Skip to main content

Table 1 HNSCC, definitive radio- radiochemotherapy by PSMD1-score

From: Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients

PSMD1-score 1 (n=29) 2 (n=26) 3 (n=27)
Age (years) mean 59.5 62.1 59.3
Q1/Q2/Q3 54/59/65 56/61.5/69.7 55/60/63
Male (%) 96.5 84.6 92.5
Weight (kg) mean 72.7 72.0 71.7
Q1/Q2/Q3 60/67/81 61.5/66/79 64.5/72/80
Smoker (n) 17/26 19/24 20/26
Karnofski >= 70 (n) 11/13 8/8 6/7
Hemoglobin level (mg/dL) mean 12.7 13.5 13.2
Q1/Q2/Q3 11.9/12.9/14 12.8/13.7/14.1 12.4/13.5/14.4
Oral cavity n (%) 4 (13.7) 3 (11.5) 5 (18.5)
Oropharynx n (%) 13 (44.8) 9 (34.5) 9 (33.3)
Hypopharynx n (%) 10 (34.4) 11 (42.2) 8 (29.6)
Larynx n (%) 2 (6.8) 3 (11.5) 5 (18.5)
cT1 n (%) 1 (3.4) 1 (3.8)  
cT2 n (%) 2 (6.8) 3 (11.5) 4 (14.8)
cT3 n (%) 11 (37.9) 6 (23.0) 7 (25.9)
cT4 n (%) 15 (51.7) 16 (61.5) 16 (59.2)
cN0 n (%) 2 (6.8) 4 (15.3) 3 (11.1)
cN1 n (%) 6 (20.6) 1 (3.8) 1 (3.7)
cN2 n (%) 19 (65.3) 20 (76.8) 21 (57.7)
cN3 n (%) 2 (6.9) 1 (3.8) 2 (7.4)
G1 n (%) 2 (6.8) 2 (7.6)  
G2 n (%) 12 (41.3) 17 (65.3) 14 (53.8)
G3 n (%) 15 (51.7) 7 (26.9) 12 (46.1)
EpoR (C20+) (%) 19 (65.5) 18 (69.2) 22 (81.4)
RT (Gy) mean 71.1 69.7 67.7
Q1/Q2/Q3 70/70.6/72 69.9/70/70.6 70/70/70.6
RT (days) 48.1 47.5 45.0
Q1/Q2/Q3 42.5/48/52 42/45.5/51 42/45/50
treated in study A1/B2/C3/D4 (n) 1/10/14/4 3/10/7/6 4/13/6/4
Local control (months) median 18.3 nr nr
Survival (months) median; 95% CI 21.2; 10.5-28.7 28.8; 6.3-42.4 43.8; 12.4-